Orange Book product · Generic (ANDA)
NEVIRAPINE
NEVIRAPINE
At a glance
Oct 06, 2017
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 06, 2017
8 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
NEVIRAPINE
Strength
400MG
Dosage form
TABLET, EXTENDED RELEASE
Route
ORAL
TE code
AB
Application
ANDA 206879
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of NEVIRAPINE
- 2012VIRAMUNE XRBrand (NDA)
NDA 201152 · BOEHRINGER INGELHEIM
- 1998VIRAMUNEBrand (NDA)
NDA 020933 · BOEHRINGER INGELHEIM
- 1996VIRAMUNEBrand (NDA)
NDA 020636 · BOEHRINGER INGELHEIM
- 2019NEVIRAPINEGeneric (ANDA)
ANDA 090688 · MACLEODS PHARMS LTD
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207684 · CIPLA
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207467 · TECH ORGANIZED
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207698 · AUROBINDO PHARMA
- 2016NEVIRAPINEGeneric (ANDA)
ANDA 208616 · AUROBINDO PHARMA
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 204621 · ALVOGEN
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 206271 · PHARMOBEDIENT
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 206448 · CIPLA
- 2014NEVIRAPINEGeneric (ANDA)
ANDA 205651 · MYLAN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
